First line therapy

DRUG2 trials

Sponsors

French Innovative Leukemia Organisation, Sun Yat-sen University

Conditions

CLL/SLLUnresectable Hepatocellular Carcinoma (HCC)

Phase 2

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Not yet recruitingNCT06739317

Sun Yat-sen UniversityUnresectable Hepatocellular Carcinoma (HCC)

Start: 2025-01-01End: 2031-06-30Target: 398Updated: 2024-12-18

Unknown Phase

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

Active, not recruitingNCT05590702

French Innovative Leukemia OrganisationCLL/SLL

Start: 2022-11-11End: 2032-12-01Target: 1000Updated: 2025-12-03